The bladder cancer landscape is evolving rapidly. The emergence of immune checkpoint inhibitors (ICIs) has fundamentally reshaped treatment, especially for muscle-invasive (MIBC) and advanced disease cases, and antibody-drug conjugates (ADCs) have introduced a new level of precision by targeting proteins like Nectin-4 commonly found on bladder cancer cells.